BRAINSTORM CELL THERAPEUTICS INC.
BCLIDrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
NurOwn® (MSC-NTF cells)
Amyotrophic Lateral Sclerosis (ALS)
NurOwn (MSC-NTF cells)
Multiple Sclerosis, Chronic Progressive
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
Amyotrophic Lateral Sclerosis
MSC-NTF cells transplantation (IM)
Amyotrophic Lateral Sclerosis
Nurown MSC-NTF cells
Amyotrophic Lateral Sclerosis (ALS)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NurOwn® (MSC-NTF cells) | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
NurOwn (MSC-NTF cells) | Phase 2 | Multiple Sclerosis, Chronic Progressive | - | - |
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
MSC-NTF cells transplantation (IM) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Nurown MSC-NTF cells | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
Amyotrophic Lateral Sclerosis (ALS)
1 drug in this indication
Multiple Sclerosis, Chronic Progressive
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)